

# Glomerulonephritis Treatment-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/GAD8251E954EN.html>

Date: February 2018

Pages: 133

Price: US\$ 3,480.00 (Single User License)

ID: GAD8251E954EN

## Abstracts

### Report Summary

Glomerulonephritis Treatment-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Glomerulonephritis Treatment industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Glomerulonephritis Treatment 2013-2017, and development forecast 2018-2023

Main market players of Glomerulonephritis Treatment in EMEA, with company and product introduction, position in the Glomerulonephritis Treatment market

Market status and development trend of Glomerulonephritis Treatment by types and applications

Cost and profit status of Glomerulonephritis Treatment, and marketing status

Market growth drivers and challenges

The report segments the EMEA Glomerulonephritis Treatment market as:

EMEA Glomerulonephritis Treatment Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Glomerulonephritis Treatment Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

ACH-5228

AMY-101

Atacicept

Avacopan

AVX-002

EMEA Glomerulonephritis Treatment Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Home Care

Clinic

Hospital

EMEA Glomerulonephritis Treatment Market: Players Segment Analysis (Company and Product introduction, Glomerulonephritis Treatment Sales Volume, Revenue, Price and Gross Margin):

Achillion Pharmaceuticals Inc

Anthera Pharmaceuticals Inc

Biogen Inc

Bristol-Myers Squibb Company

Cellmid Ltd

ChemoCentryx Inc

Complexa Inc

Dimerix Bioscience Pty Ltd

GlaxoSmithKline Plc

Merck KGaA

Omeros Corp

Pfizer Inc

Pharmalink AB

Ra Pharmaceuticals Inc

Retrophin Inc

Rigel Pharmaceuticals Inc

Shire Plc

Visterra Inc

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF GLOMERULONEPHRITIS TREATMENT**

- 1.1 Definition of Glomerulonephritis Treatment in This Report
- 1.2 Commercial Types of Glomerulonephritis Treatment
  - 1.2.1 ACH-5228
  - 1.2.2 AMY-101
  - 1.2.3 Atacicept
  - 1.2.4 Avacopan
  - 1.2.5 AVX-002
- 1.3 Downstream Application of Glomerulonephritis Treatment
  - 1.3.1 Home Care
  - 1.3.2 Clinic
  - 1.3.3 Hospital
- 1.4 Development History of Glomerulonephritis Treatment
- 1.5 Market Status and Trend of Glomerulonephritis Treatment 2013-2023
  - 1.5.1 EMEA Glomerulonephritis Treatment Market Status and Trend 2013-2023
  - 1.5.2 Regional Glomerulonephritis Treatment Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Glomerulonephritis Treatment in EMEA 2013-2017
- 2.2 Consumption Market of Glomerulonephritis Treatment in EMEA by Regions
  - 2.2.1 Consumption Volume of Glomerulonephritis Treatment in EMEA by Regions
  - 2.2.2 Revenue of Glomerulonephritis Treatment in EMEA by Regions
- 2.3 Market Analysis of Glomerulonephritis Treatment in EMEA by Regions
  - 2.3.1 Market Analysis of Glomerulonephritis Treatment in Europe 2013-2017
  - 2.3.2 Market Analysis of Glomerulonephritis Treatment in Middle East 2013-2017
  - 2.3.3 Market Analysis of Glomerulonephritis Treatment in Africa 2013-2017
- 2.4 Market Development Forecast of Glomerulonephritis Treatment in EMEA 2018-2023
  - 2.4.1 Market Development Forecast of Glomerulonephritis Treatment in EMEA 2018-2023
  - 2.4.2 Market Development Forecast of Glomerulonephritis Treatment by Regions 2018-2023

### **CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole EMEA Market Status by Types

- 3.1.1 Consumption Volume of Glomerulonephritis Treatment in EMEA by Types
- 3.1.2 Revenue of Glomerulonephritis Treatment in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in Europe
  - 3.2.2 Market Status by Types in Middle East
  - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Glomerulonephritis Treatment in EMEA by Types

## **CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Glomerulonephritis Treatment in EMEA by Downstream Industry
- 4.2 Demand Volume of Glomerulonephritis Treatment by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Glomerulonephritis Treatment by Downstream Industry in Europe
  - 4.2.2 Demand Volume of Glomerulonephritis Treatment by Downstream Industry in Middle East
  - 4.2.3 Demand Volume of Glomerulonephritis Treatment by Downstream Industry in Africa
- 4.3 Market Forecast of Glomerulonephritis Treatment in EMEA by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GLOMERULONEPHRITIS TREATMENT**

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Glomerulonephritis Treatment Downstream Industry Situation and Trend Overview

## **CHAPTER 6 GLOMERULONEPHRITIS TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA**

- 6.1 Sales Volume of Glomerulonephritis Treatment in EMEA by Major Players
- 6.2 Revenue of Glomerulonephritis Treatment in EMEA by Major Players
- 6.3 Basic Information of Glomerulonephritis Treatment by Major Players
  - 6.3.1 Headquarters Location and Established Time of Glomerulonephritis Treatment Major Players
  - 6.3.2 Employees and Revenue Level of Glomerulonephritis Treatment Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News

- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

## **CHAPTER 7 GLOMERULONEPHRITIS TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

### 7.1 Achillion Pharmaceuticals Inc

- 7.1.1 Company profile
- 7.1.2 Representative Glomerulonephritis Treatment Product
- 7.1.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Achillion Pharmaceuticals Inc

### 7.2 Anthera Pharmaceuticals Inc

- 7.2.1 Company profile
- 7.2.2 Representative Glomerulonephritis Treatment Product
- 7.2.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Anthera Pharmaceuticals Inc

### 7.3 Biogen Inc

- 7.3.1 Company profile
- 7.3.2 Representative Glomerulonephritis Treatment Product
- 7.3.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Biogen Inc

### 7.4 Bristol-Myers Squibb Company

- 7.4.1 Company profile
- 7.4.2 Representative Glomerulonephritis Treatment Product
- 7.4.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company

### 7.5 Cellmid Ltd

- 7.5.1 Company profile
- 7.5.2 Representative Glomerulonephritis Treatment Product
- 7.5.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Cellmid Ltd

### 7.6 ChemoCentryx Inc

- 7.6.1 Company profile
- 7.6.2 Representative Glomerulonephritis Treatment Product
- 7.6.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of ChemoCentryx Inc

### 7.7 Complexa Inc

- 7.7.1 Company profile
- 7.7.2 Representative Glomerulonephritis Treatment Product

7.7.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Complexa Inc

7.8 Dimerix Bioscience Pty Ltd

7.8.1 Company profile

7.8.2 Representative Glomerulonephritis Treatment Product

7.8.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Dimerix Bioscience Pty Ltd

7.9 GlaxoSmithKline Plc

7.9.1 Company profile

7.9.2 Representative Glomerulonephritis Treatment Product

7.9.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc

7.10 Merck KGaA

7.10.1 Company profile

7.10.2 Representative Glomerulonephritis Treatment Product

7.10.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Merck KGaA

7.11 Omeros Corp

7.11.1 Company profile

7.11.2 Representative Glomerulonephritis Treatment Product

7.11.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Omeros Corp

7.12 Pfizer Inc

7.12.1 Company profile

7.12.2 Representative Glomerulonephritis Treatment Product

7.12.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Pfizer Inc

7.13 Pharmalink AB

7.13.1 Company profile

7.13.2 Representative Glomerulonephritis Treatment Product

7.13.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Pharmalink AB

7.14 Ra Pharmaceuticals Inc

7.14.1 Company profile

7.14.2 Representative Glomerulonephritis Treatment Product

7.14.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Ra Pharmaceuticals Inc

7.15 Retrophin Inc

7.15.1 Company profile

- 7.15.2 Representative Glomerulonephritis Treatment Product
- 7.15.3 Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin of Retrophin Inc
- 7.16 Rigel Pharmaceuticals Inc
- 7.17 Shire Plc
- 7.18 Visterra Inc

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GLOMERULONEPHRITIS TREATMENT**

- 8.1 Industry Chain of Glomerulonephritis Treatment
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GLOMERULONEPHRITIS TREATMENT**

- 9.1 Cost Structure Analysis of Glomerulonephritis Treatment
- 9.2 Raw Materials Cost Analysis of Glomerulonephritis Treatment
- 9.3 Labor Cost Analysis of Glomerulonephritis Treatment
- 9.4 Manufacturing Expenses Analysis of Glomerulonephritis Treatment

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF GLOMERULONEPHRITIS TREATMENT**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**



## 12.1 Methodology/Research Approach

### 12.1.1 Research Programs/Design

### 12.1.2 Market Size Estimation

### 12.1.3 Market Breakdown and Data Triangulation

## 12.2 Data Source

### 12.2.1 Secondary Sources

### 12.2.2 Primary Sources

## 12.3 Reference

## I would like to order

Product name: Glomerulonephritis Treatment-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/GAD8251E954EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GAD8251E954EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970